Importance: The care of patients with head and neck cancer is labor and cost intensive. Although several studies have focused on clinical outcomes with regionalization of care of such patients, it remains uncertain if and where such concentrations of care are occurring. A better understanding of how care is distributed will improve our understanding of the financial and educational impact of compacting treatment of these patients.
Objective: To determine if regionalization of head and neck cancer care has occurred over the past decade with respect to hospital size and teaching hospital status.
Design And Setting: Secondary analysis of national health care database.
Participants: All inpatient admissions with a primary head and neck cancer diagnosis contained within the Nationwide Inpatient Sample during the calendar years 2000, 2005, and 2010.
Main Outcomes And Measures: The percentage distributions of head and neck cancer cases with respect to hospital teaching status, hospital bed size, and primary payer were compared according to calendar year to determine temporal changes. Multivariate analysis was conducted to determine year-to-year changes in proportion of head neck cancer admissions, controlling for geographic region, hospital bed size, and expected source of payment.
Results: The estimated inpatient hospital head and neck cancer stays in the United States in 2000, 2005, and 2010 (with standard error of the national estimate) were 28,862 (2067), 33,517 (3080), and 37,354 (4194), respectively. The percentage of admissions to teaching hospitals increased from 61.7% to 64.2% and 79.8%, respectively. Similarly, the percentage (with standard error) of cases in large-bed-size hospitals increased from 69.2% (2.8%) to 71.4% (3.8%) and 73.3% (4.8%), respectively. The primary expected payer distribution did not change significantly over the study (Medicare, 39.6% [1.4%]; Medicaid, 17.4% [2.2%]; private insurance, 33.3% [2.4%]; and other, 9.7% [1.5%] in 2010). The adjusted odds ratio for head neck cancer case being admitted to a teaching institution for 2010 vs 2000 was 2.5 (95% CI, 1.6-3.7).
Conclusions And Relevance: Head and neck oncologic care is increasingly being regionalized to teaching hospitals and academic centers. Such regionalization also has important implications for future education of residents and measures of achieved competency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1001/jamaoto.2013.4525 | DOI Listing |
JCO Precis Oncol
January 2025
Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with -amplified mCRC from the phase II TRIUMPH trial.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
Department of Otolaryngology Head and Neck Surgery, Nanjing Drum Tower Hospital, Jiangsu Provincial Key Medical Discipline, Nanjing University Medical School, Nanjing, 210008, China.
Cisplatin-induced ototoxicity is attributed to the aberrant accumulation of reactive oxygen species (ROS) within the inner ear. Antioxidants represented by α-lipoic acid (ALA) have been demonstrated to scavenge ROS in the cochlea, while effective delivery of these agents in vivo remains a major challenge. Here, a novel polydopamine (PDA) nanogel decorated adhesive and responsive hierarchical microcarriers for controllable is presented ALA delivery and deafness prevention.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China.
Despite substantial advances in the antitumor effects of annonaceous acetogenins (ACGs), the absence of a defined biological action mechanism remains a major barrier to their clinical application. Here, it is found that squamocin effectively depletes both EZH2 and MYC in multiple cancer cell lines, including head and neck squamous cell carcinoma, and gastric and colorectal cancer, demonstrating potent efficacy in suppressing these in vivo tumor models. Through the combination of surface plasmon resonance (SPR), differential scanning fluorimetry (DSF), and cellular thermal shift assay (CETSA), heat shock protein 90α (HSP90α) is identified as the direct binding target of squamocin.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Cariology and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China.
Chronic infectious bone destruction diseases, such as periodontitis, pose a significant global health challenge. Repairing the bone loss caused by these chronic infections remains challenging. In addition to pathogen removal, regulating host immunity is imperative.
View Article and Find Full Text PDFLangmuir
January 2025
Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.
Nanocarriers have shown significant promise in the diagnosis and treatment of various diseases, utilizing a wide range of biocompatible materials such as metals, inorganic substances, and organic components. Despite diverse design strategies, key physicochemical properties, including hydrodynamic diameter, shape, surface charge, and hydrophilicity/lipophilicity, are crucial for optimizing biodistribution, pharmacokinetics, and therapeutic efficacy. However, these properties are often influenced by drug payload, presenting an ongoing challenge in developing versatile platform technologies for theranostics.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!